PLUS1
3.40
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Market Open
Best deals to access real time data! |
|
Small Cap Basic
Monthly Subscription
for only
|
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CytoDyn Inc (QB) | CYDY | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 3.40 | 10:23:59 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 3.39 | 3.45 | 3.42 | 3.40 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 3.39 | 3.41 | 0.02 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 318 | 223,199 | $ 3.4096 | $ 761,017 | 7,852,852 | 0.261 - 10.01 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 10:23:10 | 1,000 | $ 3.40 | USD |
CytoDyn (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.94B | 569.32M | 302.11M | $ - | $ - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 26.54M | $ - | 0.00% | - | - |
CytoDyn (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 9/15/2020 | 17:06 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3) |
| 9/14/2020 | 16:31 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(7) (424b7) |
| 9/14/2020 | 10:10 | InvestorsHub NewsWire | SA Breaking News: ALYI - Alternet Systems revenue surging.. |
| 9/03/2020 | 08:45 | InvestorsHub NewsWire | Traders News Source Identifies Tomorrows NASDAQ's |
| 9/01/2020 | 17:34 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) |
| 9/01/2020 | 14:57 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 9/01/2020 | 13:47 | Edgar (US Regulatory) | Annual Statement of Changes in Beneficial Ownership (5) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYDY Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.12 | 4.27 | 3.06 | 3.61 | 3,592,030 | -0.72 | -17.48% |
| 1 Month | 3.95 | 5.15 | 3.00 | 3.92 | 3,910,091 | -0.55 | -13.92% |
| 3 Months | 9.66 | 10.01 | 2.76 | 4.79 | 7,436,244 | -6.26 | -64.8% |
| 6 Months | 0.995 | 10.01 | 0.911 | 3.99 | 7,589,569 | 2.41 | 241.71% |
| 1 Year | 0.3898 | 10.01 | 0.261 | 3.27 | 4,993,173 | 3.01 | 772.24% |
| 3 Years | 0.64 | 10.01 | 0.0552 | 2.95 | 1,895,596 | 2.76 | 431.25% |
| 5 Years | 0.77 | 10.01 | 0.0552 | 2.79 | 1,227,722 | 2.63 | 341.56% |
CytoDyn (QB) Description
| CytoDyn Inc. is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of Human Immunodeficiency Virus (HIV), Cancer, and Immunology. |
